Citigroup Reiterates Buy Rating for Bayer (BAYN)

Citigroup reaffirmed their buy rating on shares of Bayer (FRA:BAYN) in a research report released on Wednesday morning.

Other analysts have also recently issued research reports about the company. Baader Bank set a €140.00 ($166.67) price objective on Bayer and gave the stock a buy rating in a research report on Thursday, September 28th. BNP Paribas set a €130.00 ($154.76) price objective on Bayer and gave the stock a buy rating in a research report on Monday, September 25th. Warburg Research set a €121.00 ($144.05) target price on Bayer and gave the stock a buy rating in a research note on Wednesday, September 20th. Sanford C. Bernstein set a €129.00 ($153.57) target price on Bayer and gave the stock a buy rating in a research note on Friday, October 13th. Finally, equinet set a €118.00 ($140.48) target price on Bayer and gave the stock a buy rating in a research note on Friday, October 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. Bayer presently has an average rating of Buy and an average price target of €121.67 ($144.84).

Bayer (BAYN) traded down €0.12 ($0.14) during trading on Wednesday, hitting €103.48 ($123.19). The stock had a trading volume of 2,174,508 shares. The firm has a market cap of $85,470.00 and a PE ratio of 27.74. Bayer has a 52-week low of €100.60 ($119.76) and a 52-week high of €123.82 ($147.40).

TRADEMARK VIOLATION WARNING: This news story was published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3144697/citigroup-reiterates-buy-rating-for-bayer-bayn.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women?s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.